Cel-Sci Corporation (NYSEAMERICAN:CVM) Sees Large Growth in Short Interest

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totaling 718,008 shares, a growth of 172.4% from the June 30th total of 263,542 shares. Approximately 4.6% of the shares of the company are sold short. Based on an average daily volume of 399,680 shares, the short-interest ratio is currently 1.8 days.

Cel-Sci Stock Performance

NYSEAMERICAN CVM traded down $0.03 on Wednesday, hitting $1.18. 19,337 shares of the company traded hands, compared to its average volume of 271,388. The business’s 50 day moving average price is $1.24 and its 200-day moving average price is $3.05. Cel-Sci has a 52-week low of $0.89 and a 52-week high of $13.48. The company has a current ratio of 0.60, a quick ratio of 0.54 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $20.54 million, a price-to-earnings ratio of -0.12 and a beta of 0.64.

Cel-Sci (NYSEAMERICAN:CVM) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.67) EPS for the quarter.

Institutional Trading of Cel-Sci

Hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC purchased a new position in shares of Cel-Sci during the 4th quarter valued at $81,000. Vanguard Group Inc. boosted its holdings in Cel-Sci by 59.7% in the 3rd quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock worth $2,692,000 after buying an additional 109,352 shares during the period. Geode Capital Management LLC increased its stake in Cel-Sci by 30.3% in the 4th quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock worth $417,000 after buying an additional 18,432 shares in the last quarter. State Street Corp increased its stake in Cel-Sci by 9.9% in the 4th quarter. State Street Corp now owns 25,570 shares of the company’s stock worth $134,000 after buying an additional 2,300 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in Cel-Sci by 2,188.2% during the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock valued at $94,000 after acquiring an additional 39,190 shares during the period. 12.08% of the stock is owned by hedge funds and other institutional investors.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.